The HSF1 Knockout SK-OV-3 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-OV-3 human ovarian adenocarcinoma cell line. It provides a loss-of-function model for HSF1, generated through CRISPR/Cas9-mediated gene disruption. As a polyclonal pool, it offers a heterogeneous population suitable for functional studies where clonal homogeneity is not required, enabling investigation of HSF1-dependent biology in a well-characterized ovarian cancer background.
The SK-OV-3 host cell line is a human ovarian adenocarcinoma model established from malignant ascites of a patient with ovarian serous cystadenocarcinoma. These epithelial cells are p53-deficient and HER2-positive, recapitulating key features of high-grade serous ovarian cancer. SK-OV-3 cells exhibit robust tumorigenicity and are widely employed for studying ovarian cancer progression, drug resistance, and metastasis, providing a clinically relevant context for HSF1 functional analysis.
HSF1 is the master transcriptional regulator of the heat shock response, maintaining proteostasis under proteotoxic stress. In cancer, HSF1 drives a malignant transcription program supporting protein folding, proliferation, anti-apoptosis, and metastasis. Activation is mediated by upstream signals such as heat shock, growth factors (EGF, heregulin), and receptor tyrosine kinases (HER2, EGFR) via PI3K/AKT/mTOR and MAPK/ERK pathways. Upon activation, HSF1 trimerizes, translocates to the nucleus, and binds heat shock elements (HSEs) to induce targets like HSP27, HSP70, HSP90, BAG3, survivin, Mcl-1, PDL1, VEGF, and HIF1A. Post-translational modifications, including phosphorylation by mTOR, ERK, and GSK3, acetylation by p300/CBP, and sumoylation, regulate HSF1 activity. Interacting partners such as HSP90, HSP70, ATF1, NF-??B, and STAT3 coordinate stress and oncogenic transcriptional responses.
In the SK-OV-3 background, HSF1 integrates inputs from hyperactivated HER2-PI3K-AKT-mTOR and MAPK/ERK signaling, which are common in p53-deficient ovarian tumors. HSF1 likely promotes cell survival under proteotoxic and metabolic stress, contributing to drug resistance and metastasis. Disruption of HSF1 in these cells permits precise investigation of its role in maintaining the malignant phenotype, including anoikis resistance, migration, and adaptation to chemotherapeutics such as cisplatin and HSP90 inhibitors.
This polyclonal knockout model enables a broad range of functional genomics studies. Researchers can validate HSF1 loss by western blotting and RT-qPCR and assess downstream effectors (e.g., HSP70, BAG3). Cell viability (MTT), apoptosis (Annexin V), and migration/invasion (Boyden chamber) assays quantify phenotypic changes. Drug sensitivity profiling with cisplatin or HSP90 inhibitors reveals HSF1-dependent chemoresistance mechanisms. RNA-seq and ChIP-qPCR for HSE occupancy provide transcriptomic and epigenetic insights. The model also supports synthetic lethality screens and proteasome inhibition studies. For additional information, contact Ascent Research.
